SNGX Stock Overview
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.
+ 1 more risk
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.51|
|52 Week High||US$1.20|
|52 Week Low||US$0.38|
|1 Month Change||-38.87%|
|3 Month Change||-7.10%|
|1 Year Change||-50.50%|
|3 Year Change||-45.44%|
|5 Year Change||-77.25%|
|Change since IPO||-99.66%|
Recent News & Updates
U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer
Soligenix (NASDAQ:SNGX) is trading 3.2% higher after the U.S. Food and Drug Administration awarded a $2.6M grant to support a study of expanded HyBryte treatment to treat T-cell lymphoma, including at-home usage. HyBryte is a skin directed photodynamic therapy for cutaneous T-cell lymphoma (CTCL), a rare skin disease and cancer. The Orphan Products Development grant, totaling $2.6M over four years, was awarded to an academic institution that was a leading enroller in Soligenix's successful Phase 3 study in the treatment of early stage CTCL. The treatment is expected to launch in Q4.
Soligenix announces $2.6M FDA grant to further study blood cancer candidate
Clinical-stage biotech Soligenix, Inc. (NASDAQ:SNGX) announced Tuesday that the FDA had awarded a $2.6M grant to support studies for its experimental therapy HyBryte for expanded treatment in early-stage cutaneous T-Cell Lymphoma (CTCL). A photodynamic therapy, HyBryte, also known as SGX301, uses safe, visible light for activation. CRCL is a form of non-Hodgkin's lymphoma, a cancer involving white blood cells, which are essential for the body's immune function. The FDA's four-year Orphan Products Development grant was awarded to an academic institution that led the enrollment in the Phase 3 FLASH trial for the candidate in the treatment of early CTCL, SNGX said. The 50-patient trial for HyBryte will be conducted as an open-label study involving the highest enrolling clinical centers that took part in the FLASH study. The trial, named RW-HPN-MF-01, is expected to start in Q4 2022. Read more on data from the FLASH trial.
Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M
Soligenix press release (NASDAQ:SNGX): Q2 GAAP EPS of -$0.06 beats by $0.03. Revenue of $0.4M (+100.0% Y/Y) beats by $0.2M. As of June 30, 2022, the Company's cash position was approximately $20.2 million. Shares +5% PM.
|SNGX||US Biotechs||US Market|
Return vs Industry: SNGX underperformed the US Biotechs industry which returned -30.9% over the past year.
Return vs Market: SNGX underperformed the US Market which returned -21.6% over the past year.
|SNGX Average Weekly Movement||9.3%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.9%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: SNGX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: SNGX's weekly volatility (9%) has been stable over the past year.
About the Company
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer.
Soligenix Fundamentals Summary
|SNGX fundamental statistics|
Is SNGX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SNGX income statement (TTM)|
|Cost of Revenue||US$687.48k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.35|
|Net Profit Margin||-1,710.45%|
How did SNGX perform over the long term?See historical performance and comparison
Is SNGX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SNGX?
Other financial metrics that can be useful for relative valuation.
|What is SNGX's n/a Ratio?|
Price to Sales Ratio vs Peers
How does SNGX's PS Ratio compare to its peers?
|SNGX PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
ONVO Organovo Holdings
ABVC ABVC BioPharma
NHWK NightHawk Biosciences
AGTC Applied Genetic Technologies
Price-To-Sales vs Peers: SNGX is good value based on its Price-To-Sales Ratio (24.9x) compared to the peer average (39.5x).
Price to Earnings Ratio vs Industry
How does SNGX's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: SNGX is expensive based on its Price-To-Sales Ratio (24.9x) compared to the US Biotechs industry average (13x)
Price to Sales Ratio vs Fair Ratio
What is SNGX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||24.9x|
|Fair PS Ratio||29.5x|
Price-To-Sales vs Fair Ratio: SNGX is good value based on its Price-To-Sales Ratio (24.9x) compared to the estimated Fair Price-To-Sales Ratio (29.5x).
Share Price vs Fair Value
What is the Fair Price of SNGX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate SNGX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SNGX's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
How is Soligenix forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SNGX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SNGX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SNGX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SNGX's revenue (117.7% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: SNGX's revenue (117.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SNGX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Soligenix performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SNGX is currently unprofitable.
Growing Profit Margin: SNGX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SNGX is unprofitable, and losses have increased over the past 5 years at a rate of 18.1% per year.
Accelerating Growth: Unable to compare SNGX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SNGX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: SNGX has a negative Return on Equity (-357.29%), as it is currently unprofitable.
Discover strong past performing companies
How is Soligenix's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: SNGX's short term assets ($20.8M) exceed its short term liabilities ($8.8M).
Long Term Liabilities: SNGX's short term assets ($20.8M) exceed its long term liabilities ($8.3M).
Debt to Equity History and Analysis
Debt Level: SNGX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if SNGX's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SNGX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SNGX has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 17% each year.
Discover healthy companies
What is Soligenix current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SNGX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SNGX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SNGX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SNGX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SNGX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Christopher Schaber (56 yo)
Dr. Christopher J. Schaber, Ph D., has been the President and Chief Executive Officer at Soligenix, Inc. since August 30, 2006. Dr. Schaber has broad experience in the pharmaceutical and biotechnology indu...
CEO Compensation Analysis
Compensation vs Market: Christopher's total compensation ($USD687.41K) is about average for companies of similar size in the US market ($USD776.35K).
Compensation vs Earnings: Christopher's compensation has been consistent with company performance over the past year.
Experienced Management: SNGX's management team is seasoned and experienced (8.2 years average tenure).
Experienced Board: SNGX's board of directors are seasoned and experienced ( 13.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|18 May 22||BuyUS$8,866||Christopher Schaber||Individual||20,000||US$0.44|
|18 May 22||BuyUS$4,000||Richard Straube||Individual||8,000||US$0.50|
|17 Dec 21||BuyUS$5,179||Christopher Schaber||Individual||7,000||US$0.74|
|15 Dec 21||BuyUS$7,819||Jonathan Guarino||Individual||11,000||US$0.71|
|14 Dec 21||BuyUS$7,269||Christopher Schaber||Individual||10,000||US$0.73|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.5%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Soligenix, Inc.'s employee growth, exchange listings and data sources
- Name: Soligenix, Inc.
- Ticker: SNGX
- Exchange: NasdaqCM
- Founded: 1987
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$21.872m
- Shares outstanding: 43.11m
- Website: https://www.soligenix.com
Number of Employees
- Soligenix, Inc.
- 29 Emmons Drive
- Suite B-10
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SNGX||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Jun 1987|
|DOA2||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 1987|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/23 00:00|
|End of Day Share Price||2022/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.